Activaero appoints Christian Pangratz as new Chief Business Officer
Activaero GmbH, a leader in controlled breathing inhalation technologies and therapeutics, today announced the appointment of Christian M. Pangratz as Chief Business Officer.[more]
Activaero raises EUR 5.0 Million ($ 6.8 Million) in a second closing series a round led by LSP
Gemuenden/Wohra, February 16, 2011 - Activaero today announced that it has closed a further financing round of 5.0 Mio Euros with LSP Life Sciences Partners from the Netherlands. Activaero will use the proceeds to further develop...[more]
ACTIVAERO SIGNS COLLABORATION WITH FOREST HEALTHCARE B.V. FOR CYSTIC FIBROSIS
Gemuenden (Wohra), Germany - January 26, 2011- Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled therapeutic agents, today announced that it has signed a collaboration agreement...[more]
Activaero is a "Hessen Champion 2010": Winner of the Special Award "New products and developments"
Gemuenden (Wohra) 28 October 2010 - Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled therapeutic agents, today announced that it has just won an award in the competition "Hessen...[more]
AKITA JET- Development of European sales activities
Activaero has requested that health insurance companies in different European countries offer reimbursement for the AKITA JET inhalation system. In Germany, reimbursement for certain medications has already been established. [more]
AICS study off to a successful start
With support from external investors, Activaero is now in the position to begin its own clinical program. The goal is to deliver well-known medications to the lungs using the AKITA inhalation system and in turn, develop and...[more]
Activaero's AKITA JET Receives FDA 510(K) Clearance
Dublin, Ohio, December 9, 2009 - Activaero, the world leader in the design of controlled breathing drug delivery technologies that maximize the efficiency and precision of inhaled drugs, today announced that the US Food and Drug...[more]
Activaero closes a 10.7 Million Euro Series a Financing
Gemuenden, Germany and Dublin, Ohio (USA), October 29, 2009 - Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled therapeutic agents, announced today the closing of a Series A...[more]
Activaero Extends Management Team with Three Senior Appointments and John Patton Joins Supervisory Board
Gemünden (Wohra), Germany, October 19, 2009 - Activaero GmbH, the world leader in the design of controlled breathing drug delivery technologies that maximize the efficiency and precision of inhaled drugs, today announced that it...[more]
bitop AG and Activaero collaborate on clinical study of inhalable ECOTIN-Solution
Witten/Gemünden (Wohra), Germany; June 17, 2009 - bitop AG and Activaero GmbH today announced the start of a clinical study on bitop AG's medical device ECOTIN inhalation solution using Activaero's leading controlled breathing...[more]